2022 ETA Consensus Statement: what are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer?

in European Thyroid Journal
View More View Less
  • 1 F Pacini, Endocrinology, University of Siena, Siena, 53100, Italy
  • | 2 G Fuehrer-Sake, Essen, Germany
  • | 3 R Elisei, Pisa, Italy
  • | 4 D Handkiewicz-Junak, NUclear Medicine and Endocrine Oncology Department, Maria Sklodowska-Curie National Research Institute of Oncology Gliwice Branch, Gliwice, 44-102, Poland
  • | 5 S Leboulleux, Gustave Roussy, Villejuif, 94805, France
  • | 6 M Luster, Department of Nuclear Medicine, University of Marburg, Marburg, Germany
  • | 7 M Schlumberger, Gustave Roussy, Villejuif, France
  • | 8 J Smit, Radboud Universiteit, Nijmegen, Netherlands

Correspondence: Daria Handkiewicz-Junak, Email: Daria.Handkiewicz-Junak@io.gliwice.pl
Open access

Modern use of postoperative radioactive iodine (RAI) treatment for differentiated thyroid cancer (DTC) should be implemented in line with patients' risk stratification. Although beneficial effects of radioiodine are undisputed in high-risk patients, controversy remains in intermediate-risk and some low-risk patients. Since the last consensus on post-surgical use of RAI in DTC patients, new retrospective data and results of prospective randomized trials have been published, which have allowed the development of a new European Thyroid Association statement for the indications of post-surgical RAI therapy in DTC. Questions about which patients are candidates for RAI therapy, which activities of RAI can be used, and which modalities of pre-treatment patient preparation should be used are addressed in the present guidelines.

 

European Thyroid Association
Sept 2018 onwards Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 68 68 35
PDF Downloads 104 104 62